Rosalind P Candelaria
Overview
Explore the profile of Rosalind P Candelaria including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
607
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yam C, Mittendorf E, Garber H, Sun R, Damodaran S, Murthy R, et al.
Breast Cancer Res Treat
. 2023 Apr;
199(3):457-469.
PMID: 37061619
Purpose: Neoadjuvant anti-PD-(L)1 therapy improves the pathological complete response (pCR) rate in unselected triple-negative breast cancer (TNBC). Given the potential for long-term morbidity from immune-related adverse events (irAEs), optimizing the...
12.
Abuhadra N, Sun R, Bassett Jr R, Huo L, Chang J, Teshome M, et al.
Invest New Drugs
. 2023 Apr;
41(3):391-401.
PMID: 37043123
No abstract available.
13.
Panthi B, Adrada B, Candelaria R, Guirguis M, Yam C, Boge M, et al.
Cancers (Basel)
. 2023 Feb;
15(4).
PMID: 36831368
Early assessment of neoadjuvant systemic therapy (NAST) response for triple-negative breast cancer (TNBC) is critical for patient care in order to avoid the unnecessary toxicity of an ineffective treatment. We...
14.
Zhou Z, Adrada B, Candelaria R, Elshafeey N, Boge M, Mohamed R, et al.
Sci Rep
. 2023 Jan;
13(1):1171.
PMID: 36670144
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Neoadjuvant systemic therapy (NAST) followed by surgery are currently standard of care for TNBC with 50-60% of patients achieving...
15.
Wu C, Jarrett A, Zhou Z, Elshafeey N, Adrada B, Candelaria R, et al.
Cancer Res
. 2022 Aug;
82(18):3394-3404.
PMID: 35914239
Significance: Integrating MRI data with biologically based mathematical modeling successfully predicts breast cancer response to chemotherapy, suggesting digital twins could facilitate a paradigm shift from simply assessing response to predicting...
16.
Yam C, Abuhadra N, Sun R, Adrada B, Ding Q, White J, et al.
Clin Cancer Res
. 2022 May;
28(13):2878-2889.
PMID: 35507014
Purpose: Metaplastic breast cancer (MpBC) is a rare subtype of breast cancer that is commonly triple-negative and poorly responsive to neoadjuvant therapy in retrospective studies. Experimental Design: To better define...
17.
Musall B, Adrada B, Candelaria R, Mohamed R, Abdelhafez A, Son J, et al.
J Magn Reson Imaging
. 2022 May;
56(6):1901-1909.
PMID: 35499264
Background: Pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC) is a strong predictor of patient survival. Edema in the peritumoral region (PTR) has been...
18.
Candelaria R, Adrada B, Lane D, Rauch G, Moulder S, Thompson A, et al.
Ultrasound Med Biol
. 2022 Mar;
48(6):1010-1018.
PMID: 35300879
This study aimed to investigate mid-treatment breast tumor ultrasound characteristics that may predict eventual pathologic complete response (pCR) in triple-negative breast cancer; specifically, we examined associations between pCR and two...
19.
Jimenez J, Abdelhafez A, Mittendorf E, Elshafeey N, Yung J, Litton J, et al.
Eur J Radiol
. 2022 Feb;
149:110220.
PMID: 35193025
Purpose: We aimed to develop a predictive model based on pretreatment MRI radiomic features (MRIRF) and tumor-infiltrating lymphocyte (TIL) levels, an established prognostic marker, to improve the accuracy of predicting...
20.
Huang M, Hess K, Ma J, Santiago L, Scoggins M, Arribas E, et al.
Acad Radiol
. 2021 Sep;
29(7):1039-1045.
PMID: 34538550
Rationale And Objectives: Synthesized mammography with digital breast tomosynthesis (SM+DBT) and full-field digital mammography with DBT were prospectively evaluated for recall rate (RR), cancer detection rate (CDR), positive predictive value...